Intraday Info: Exelixis, Inc. (NASDAQ:EXEL) locked on 13/12/2016 at $16.16. It has average volume $7.02 million whilst it total volume $4,101,124. The company has EPS -0.62 and according to analysts next quarter EPS and next year estimate EPS will -0.01 and -0.02 respectively. And it total income -149.00 million.Ownership Summary: Exelixis Inc., has total institutional ownership 76.20% while its total outstanding shares 286 millions that’s value of holdings $3,588 million.

Active Positions: In the latest year, EXEL 142 holders have raised its positions while it contains total 51,461,758 shares. And the strength of reduced positions holders and held positions holders are 64 and 18 respectively.

New and Sold Out Positions: In EXEL force of new positions holders 57 and it has total shares 18,509,886. And force of sold out positions holders 20 and it has 6,822,719 shares.

Comparison with Other Company: The Market Value of EXEL is $4M above from Charles River Laboratories International, Inc. market value which is $3M. Current Last Sale of EXEL is $16.16 below from CRL current last sale which is $75.44.

Exelixis, Inc. said economic results for the 1/3 region of 2016 and offered an update on development closer to turning in upon its key 2016 corporate targets, further to business and clinical improvement milestones.

Exelixis is focused on the U.S. release of CABOMETYX™ (cabozantinib) tablets as a remedy for sufferers with superior renal mobile carcinoma (RCC) who’ve received earlier anti-angiogenic therapy. CABOMETYX generated $31.2 million in net product sales throughout the third quarter of 2016, which displays the first complete sector of product sales. net product sales for the third sector of 2016, counting income of COMETRIQ® (cabozantinib) capsules for the remedy of sure kinds of thyroid cancer, had been $42.7 million. even as Exelixis specializes in commercialization in the u.s., its accomplice Ipsen is inside the manner of launching CABOMETYX in the ecu Union, following the european commission’s (EC) September 2016 approval of CABOMETYX for the treatment of grownup patients with advanced RCC who’ve acquired prior vascular endothelial boom thing (VEGF)-focused remedy. Exelixis is eligible to get hold of royalties on CABOMETYX income by means of Ipsen outdoor of the usa, Canada and Japan.



Please enter your comment!
Please enter your name here